Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2 – clinical implications

@inproceedings{akir2010SomatostatinRB,
  title={Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2 – clinical implications},
  author={M. Cihan Çakir and Dorota Dworakowska and Ashley B. Grossman},
  booktitle={Journal of cellular and molecular medicine},
  year={2010}
}
In part 1 of our review on somatostatin (SST) receptor biology in neuroendocrine tumours, the somatostatin receptor (SSTR) as a G-protein coupled receptor (GPCR), and the anti-tumour effects of SST and SSTR post-signalling pathways, were reviewed. To recapitulate, SST is a peptide hormone which acts mainly as an inhibitor in many endocrine systems. SST has five receptor subtypes (SSTR1–5) with SSTR2 as the most commonly expressed form in both normal and tumoral tissues. SST has been widely… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
SST has been widely investigated for its anti - tumoral effects and their mechanisms , and currently there are two SST analogues ( lanreotide and octreotide ) in clinical use .
SST has been widely investigated for its anti - tumoral effects and their mechanisms , and currently there are two SST analogues ( lanreotide and octreotide ) in clinical use .
SST has been widely investigated for its anti - tumoral effects and their mechanisms , and currently there are two SST analogues ( lanreotide and octreotide ) in clinical use .
SST has been widely investigated for its anti - tumoral effects and their mechanisms , and currently there are two SST analogues ( lanreotide and octreotide ) in clinical use .
All Topics